Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

This study has been withdrawn prior to enrollment.
(This study was stopped due to poor enrollment numbers)
Sponsor:
Collaborator:
Information provided by:
University of Utah
ClinicalTrials.gov Identifier:
NCT00722254
First received: July 23, 2008
Last updated: February 17, 2009
Last verified: February 2009
  Purpose

To determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension, and to discover if the fibrosis in these patients is primary (AMM) or secondary.


Condition
Primary Myelofibrosis
Primary Pulmonary Hypertension
Secondary Myelofibrosis
Pulmonary Arterial Hypertension

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

Resource links provided by NLM:


Further study details as provided by University of Utah:

Primary Outcome Measures:
  • Determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension [ Time Frame: After sample is obtained ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Discover if the fibrosis in patients with primary pulmonary hypertension is primary (AMM) or secondary. [ Time Frame: After sample is obtained ] [ Designated as safety issue: No ]
  • Clonality [ Time Frame: After sample is obtained ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Whole Blood


Estimated Enrollment: 60
Study Start Date: June 2006
Estimated Study Completion Date: March 2010
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
PPH
Subjects diagnosed with primary pulmonary hypertension (PPH)
Myelofibrosis
Subjects diagnosed with Primary or Secondary Myelofibrosis

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients suffering from primary pulmonary hypertension or myelofibrosis (primary or secondary)

Criteria

Inclusion Criteria:

  1. > 18 years of age
  2. Signed Informed Consent
  3. Subjects diagnosed with Primary Pulmonary Hypertension or Myelofibrosis (primary or secondary)

Exclusion Criteria:

  1. Anyone not meeting the above inclusion criteria
  2. Pregnant women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00722254

Locations
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84132
VA Salt Lake City Health Care System
Salt lake City, Utah, United States, 84148
Sponsors and Collaborators
University of Utah
Investigators
Principal Investigator: Josef T Prchal, MD University of Utah
  More Information

Publications:

Responsible Party: Josef T. Prchal, MD, University of Utah
ClinicalTrials.gov Identifier: NCT00722254     History of Changes
Other Study ID Numbers: 17806
Study First Received: July 23, 2008
Last Updated: February 17, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by University of Utah:
Myeloproliferative Disorder
Primary Myelofibrosis
Primary Pulmonary Hypertension
Secondary Myelofibrosis
Pulmonary Arterial Hypertension
Flolan
Clonality
CD34+ cells
Hematologic abnormalities

Additional relevant MeSH terms:
Primary Myelofibrosis
Hypertension, Pulmonary
Hypertension
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on July 28, 2014